Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by US Bancorp DE

US Bancorp DE raised its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,680 shares of the medical research company’s stock after acquiring an additional 87 shares during the quarter. US Bancorp DE’s holdings in Bio-Rad Laboratories were worth $3,180,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Bio-Rad Laboratories by 1.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock worth $147,583,000 after acquiring an additional 4,260 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in Bio-Rad Laboratories by 3.9% in the third quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company’s stock valued at $84,571,000 after purchasing an additional 9,584 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Bio-Rad Laboratories in the third quarter valued at $83,681,000. Mawer Investment Management Ltd. increased its stake in Bio-Rad Laboratories by 63.0% in the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after purchasing an additional 84,237 shares during the last quarter. Finally, Fisher Asset Management LLC increased its stake in Bio-Rad Laboratories by 15.2% in the fourth quarter. Fisher Asset Management LLC now owns 106,871 shares of the medical research company’s stock valued at $35,108,000 after purchasing an additional 14,135 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Price Performance

BIO stock opened at $258.37 on Friday. The stock has a 50-day moving average price of $322.58 and a two-hundred day moving average price of $331.14. Bio-Rad Laboratories, Inc. has a 12-month low of $248.22 and a 12-month high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The company has a market cap of $7.24 billion, a PE ratio of -3.97 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BIO. Wells Fargo & Company dropped their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.